Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP®, Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines, Gilead Sciences Statement on the Solidarity Trial, Statement from Brett Pletcher on Gilead Sciences Settlement Over Charitable Donations. “Congress should require the NIH to enforce the Bayh-Dole obligation to make the Kite Pharma Chimeric Antigen Receptors Technologies (CAR T) treatments available to the public on reasonable terms. Novel therapeutics developer Gilead Sciences announced plans to acquire chimeric antigen receptor T-cell (CAR-T) innovator Kite Pharma, Inc. in a deal valued at $11.9 billion. The … Stocks Analysis by Zacks Investment Research covering: S&P 500, Gilead Sciences Inc, Novartis AG ADR, AbbVie Inc. Read Zacks Investment Research's latest article on Investing.com Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. In a bid to diversify its portfolio and boost growth, Gilead Sciences has agreed to acquire Kite Pharma, a Santa Monica, Calif.-based immunotherapy specialist, for $11.9 billion. Kite Pharma, Inc. KITE announced the acquisition of a privately held Netherlands-based biotechnology company, T-Cell Factory B.V. (TCF). The company has developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR), depending on the type of cancer. The acquisition of Kite would be Gilead’s biggest purchase, surpassing its $11 billion deal for Pharmasset in 2011, according to Standard & Poor’s Global Market Intelligence.. Following successful completion of the tender offer, Gilead will acquire all remaining shares not tendered in the offer through a second step merger at the same price as in the tender offer. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. David Chang, M.D., Ph.D., Kite Pharma's executive vice president, R&D, and chief medical officer, said, "In addition to expanding our capabilities in TCR, this acquisition is an important first step in our goal of global clinical expansion outside the U.S., applying our leadership and in-house clinical expertise in both CAR and TCR therapies.” Please call the Commission at 1-800-SEC-0330 for further information on the public reference room. It is expected to be the first to market as a treatment for refractory aggressive non-Hodgkin lymphoma, which includes diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL). FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead (“Purchaser”), to acquire Kite Pharma, Inc. (Nasdaq: KITE) for $180 per share, net to the seller in cash, without interest, or approximately $11.9 billion in the aggregate. -- Immediately Positions Gilead as a Leader in Cell Therapy --, -- Kite's Lead CAR T Therapy Candidate, Axicabtagene Ciloleucel, Under Priority Review in the U.S. and Expedited Review in the EU --, -- Provides Broad Pipeline in Hematologic Malignances and Solid Tumors and Robust Platform for Continued Innovation --, -- Leverages Gilead's Expertise in Rapidly Advancing Therapies to Address Unmet Patient Needs --. To say the Read More. The company is focused on chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies designed to empower the immune system's ability to recognize and kill tumors. For the latest updates on our ongoing response to COVID-19, please click here. The company’s research confirmed that the acquisition of Kite Pharma by Gilead Sciences for $11.9 billion was the biggest deal of the quarter. Gilead plans to finance the transaction with a combination of cash on hand, bank debt and senior unsecured notes. Gilead has paid $11.9 billion to make Kite a wholly owned subsidiary. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of the companies' and members of their senior management team. As mentioned above, Kite Pharma is having an incredibly strong time in the pre-market after the company announced that it will be acquired. A marketing authorization application (MAA) has also been filed for axi-cel for the treatment of relapsed/refractory DLBCL, TFL and PMBCL with the European Medicines Agency (EMA), representing the first submission in Europe for a CAR T therapy. In March 2015, Kite Pharma acquired T-Cell Factory(TCF), a privately held biotechnology company based in the Netherlands, for €20 million and renamed it – Kite Pharma EU. Our goal is to fundamentally change the way people think about cancer treatment by pushing the boundaries of what is possible with cell therapy — using genetically modified immune cells to target tumors. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support For more information on cell therapy and Kite Pharma, see www.kitepharma.com. Gilead Sciences (NASDAQ: GILD) announced on Monday that it was acquiring Kite Pharma (NASDAQ: KITE) for $11.9 billion. Gilead's and Kite's filings with the Commission are also available to the public from commercial document-retrieval services and at the website maintained by the Commission at www.sec.gov. In my June article, I had discussed why Gilead should foray into CAR-T. A talent acquisition (TA) partner will review your application based on the position requirements (education, work experience and overall background) and your submitted profile. Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. Kite Pharma, Inc.KITE announced the acquisition of a privately held Netherlands-based biotechnology company, T-Cell Factory B.V. (TCF). I don't second-guess Gilead's $11.9 billion offer for Kite at all. This Smart News Release features multimedia. Transactions are recorded by the highest transaction dollar value (rather than using the inflation adjusted values). Kite Pharma is a division of Gilead Sciences based in California. "From the release of our pivotal data for axi-cel, to our potential approval by the FDA, this is a year of milestones. On March 31, 2017, Kite submitted a Biologics License Application to the FDA for its lead product candidate, axi-cel, as a treatment for patients with relapsed or refractory aggressive non-Hodgkin lymphoma who are ineligible for autologous stem cell transplant. Buried in among Gilead’s fourth-quarter results statement is a line revealing it has abandoned an anti-BCMA cell therapy for multiple myeloma, part of its $12 billion acquisition … … Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. © 2020 Gilead Sciences, Inc. All rights reserved. This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares of Kite. For more on Kite’s acquisition by Gilead Sciences in 2017, read the press release. August 29, 2017 August 29, 2017 Jim. With the addition of Kite’s CAR T and TCR cellular therapy platforms, we believe that together we can bring that same kind of innovation to cancer. Additional Information and Where to Find It. Gilead Completes Acquisition of Kite Pharma. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation and disclaim any intent to update any such forward-looking statements. Not a one-and-done acquisition. See Our Mission. “Frederick County is noted for their bio-medical industries and research, and Kite Pharma is an exceptional addition to their … Developer of active immunotherapies for cancer intended to cure cancer. Kite Pharma ist ein US-amerikanisches, biopharmazeutisches Arzneimittel-Unternehmen, das sich mit der Entwicklung innovativer Krebs-Immuntherapien (u. a. CAR-T-Zell-Therapie) beschäftigt.Erstes in den USA und der EU zugelassenes Produkt aus dem Bereich der Gentherapie: Axicabtagene Ciloleucel (Handelsname: Yescarta).. Im Oktober 2017 gab Gilead Sciences bekannt, Kite Pharma … We are greatly impressed with the Kite team and what they have accomplished, and share their belief that cell therapy will be the cornerstone of treating cancer. A recent analysis by GlobalData, a leading data and analytics company, identified the top 10 pharma companies by deal value for quarter 3, in 2017, revealed a number of key insights. A solicitation and an offer to buy shares of Kite will be made only pursuant to an offer to purchase and related materials that Gilead intends to file with the U.S. Securities and Exchange Commission. KITE Gains On Acquisition News . For the latest updates on our ongoing response to COVID-19, please, Clinical Trials Transparency & Data Sharing Policy. For the latest updates on our ongoing response to COVID-19, please, Clinical Trials Transparency & Data Sharing Policy. For more information on Gilead Sciences, please visit the company's website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. The acquisition of Kite Pharma by Gilead Sciences, originally announced in August 2017, was completed this month. This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, related to Gilead, Kite and the acquisition of Kite by Gilead that are subject to risks, uncertainties and other factors. Gilead Sciences just announced a huge, major acquisition in the CAR-T space - that of Kite Pharma. It started with the late 2017 acquisition of Kite Pharma for $11.9 billion. Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. "The field of cell therapy has advanced very quickly, to the point where the science and technology have opened a clear path toward a potential cure for patients. The Offer to Purchase, the related Letter of Transmittal and certain other offer documents, as well as the Solicitation/Recommendation Statement, will be sent to all stockholders of Kite at no expense to them. The KITE acquisition will spur a number of acquisitions … But what Gilead saw this year gave Milligan the confidence to buy Kite Pharma, one of CAR-T's leaders, in a $11.9 billion deal that drew instant comparisons to … Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term, durable response and eliminating the burden of chronic care. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. Dig Deeper. Some content on this site is not intended for people outside the United States. Biotech giant Gilead Sciences, Inc. (GILD) announced that it will buy Kite Pharma, Inc. (KITE) to foray into the emerging field of cell therapy. ", Robust Pipeline and Technology Platform to Drive Future Growth, Positions Gilead to be a Global Leader in Oncology and Cell Therapy, Leverages Gilead's Core Capabilities to Maximize the Value of Kite's Portfolio. Kite is an industry leader in the emerging field of cell therapy, which uses a patient's own immune cells to fight cancer. Research and development as well as the commercialization operations for Kite will remain based in Santa Monica, California, with product manufacturing remaining in El Segundo, California. The company is engaged in developing engineered cell therapies that express either a chimeric antigen receptor (CAR) or a T … Gilead isn't buying Kite Pharma just for the drugs it's developing. Free copies of these materials and certain other offering documents will be made available by Gilead by mail to Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, attention: Investor Relations, by phone at 1-800-GILEAD-5 or 1-650-574-3000, or by directing requests for such materials to the information agent for the offer, which will be named in the Tender Offer Statement. Added David Chang, M.D., Ph.D., Kite Pharma's evp, research and development and CMO: “In addition to expanding our capabilities in TCR, this acquisition is … This submission comes after positive results from Kite's ZUMA-1 pivotal trial with axi-cel in patients with chemorefractory aggressive non-Hodgkin lymphoma. Kite Pharma has acquired in 1 US state, and 2 countries. Gilead Sciences caught an upgrade Thursday following its Kite Pharma buyout and the likelihood its new CAR-T cancer medications will allow it to diversify away … Kite is a leader in the emerging field of cell therapy, in which a person’s immune cells are activated to fight cancer. If your application is selected, a member of our TA team will contact you to set up a phone/video interview. These potential Each and every accomplishment is a reflection of the talent that is unique to Kite. The consummation of the tender offer is subject to various conditions, including a minimum tender of at least a majority of outstanding Kite shares on a fully diluted basis, the expiration or termination of the waiting period under the Hart Scott Rodino Antitrust Improvements Act, and other customary conditions. Skadden, Arps, Slate, Meagher & Flom is serving as legal counsel to Gilead and Sullivan & Cromwell LLP and Cooley LLP are serving as legal counsel to Kite. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California. Our similar cultures and histories of driving rapid innovation in order to bring more effective and safer products to as many patients as possible make this an excellent strategic fit.". Now Gilead is betting that Kite can provide a similar payoff. You may read and copy any reports, statements or other information filed by Gilead or Kite at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Kite is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. View source version on businesswire.com: http://www.businesswire.com/news/home/20170828005415/en/, GileadSung Lee, 650-524-7792InvestorsorAmy Flood, 650-522-5643MediaorKiteChristine Cassiano, 424-532-5084Investors & Media. Under the terms of the merger agreement, a wholly-owned subsidiary of Gilead will promptly commence a tender offer to acquire all of the outstanding shares of Kite's common stock at a price of $180.00 per share in cash. Gilead Completes Acquisition of Kite Pharma Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. The following table lists the largest mergers and acquisitions in the pharmaceutical and biotechnology industry (those over $10 billion). Over the past 30 years, Gilead has made significant advances that have improved the lives of people living with HIV and, over the past four years, has introduced four medicines that offer a cure for chronic hepatitis C virus. Biotech giant Gilead Sciences, Inc. (GILD) announced that it will buy Kite Pharma, Inc. (KITE) to foray into the emerging field of cell therapy. Kite Pharma General Information Description. Investors had long waited for the big biotech to make a deal. Kite and Gilead will have exclusive rights to develop and commercialize therapies based on these targets or antibodies. FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash. Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP®, Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines, Gilead Sciences Statement on the Solidarity Trial, Statement from Brett Pletcher on Gilead Sciences Settlement Over Charitable Donations, http://www.businesswire.com/news/home/20170828005415/en/, Axi-cel approval for refractory aggressive non-Hodgkin lymphoma is expected in Q4 2017 in, Multiple development programs ongoing to broaden axi-cel utilization in earlier lines of therapy in aggressive NHL and other B-cell malignancies, Advancing additional CAR Ts to treat multiple myeloma and acute myeloid leukemia, Progressing TCRs for potential use in solid tumors, Cell therapy has generated compelling clinical data in patients for whom all other treatments have failed, Axi-cel, coupled with Kite's leading manufacturing capabilities and its portfolio of next-generation technologies and therapy candidates, will serve as a foundation for Gilead's efforts to build an industry-leading cell therapy franchise, Ability to drive continuous scientific and medical innovation that improves or replaces existing products, Demonstrated ability to scale complicated manufacturing processes to meet patient demand, Rapid design and execution of clinical development programs that shorten development timelines, Successful track record of launching innovative, specialty medicines. Kite is based in Santa Monica, California. The combined strength of Kite and Gilead allows us to remain innovative, agile, and ambitious in our mission to keep improving the lives of people with all types of cancer. Forward-looking statements include, without limitation, statements regarding the business combination; its effect on Gilead's revenues and earnings; the commercial success of Kite's products; approval of axi-cel by the FDA; approval of axi-cel by the EMA; the ability of Gilead to advance Kite's product pipeline, including axi-cel; the anticipated timing of clinical data; the possibility of unfavorable results from clinical trials; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction in a timely manner or at all; difficulties or unanticipated expenses in connection with integrating the companies; and the accuracy of any assumptions underlying any of the foregoing. In an Aug. 28 research report, Maxim Group took a look at Gilead Sciences Inc.'s (GILD:NASDAQ) plans to acquire Kite Pharma (KITE:NASDAQ), "an industry leader in the emerging field of cell therapy," as described by analyst Jason Kolbert.The former "is acquiring all of the outstanding shares of common stock at a price of $180 per share in cash" and "plans to … Gilead has paid $11.9 billion to make Kite a wholly owned subsidiary. The tender offer is not subject to a financing condition. Source: Streetwise Reports Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term, durable response and eliminating the burden of chronic care. Kite Pharma General Information Description. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support On Monday, Gilead acquired KITE for $180 per share. Gilead has completed its $11.9 billion landmark acquisition of Kite Pharma, as the pharma switches focus from hepatitis C to cancer and revolutionary CAR-T therapies. The acquisition of Kite Pharma by Gilead Sciences, originally announced in August 2017, was completed this month. Kite Pharma has already hired 100 employees for this facility and is expecting to employ 400-700 individuals by the end of 2025. Kite Pharma, then trading at about $55, was among them. Register for more free articles. Stay logged in to skip the surveys. KEI notes that Kite reported spending $317 million in R&D from 2012 to June 30, 2017, and is … Gilead Sciences, Inc. today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead , to acquire... | January 16, 2021 Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Kite Pharma’s largest acquisition to date was in 2017, when it acquired Cell Design Labs for $567M. With Gilead's expertise and support, we hope to fulfill that potential by rapidly accelerating our robust pipeline and next-generation research and manufacturing technologies for the benefit of patients around the world. The transaction will provide opportunities for diversification of revenues, and is expected to be neutral to earnings by year three and accretive thereafter. At 8:00 a.m. Eastern Time today, Gilead's management will host a conference call and a simultaneous webcast to discuss the transaction. KEI statement regarding Gilead’s Acquisition of Kite Pharma. The deal for Kite would be one of Gilead’s biggest, rivaling the company’s $11 billion purchase of liver-disease drugmaker Pharmasset in 2012. "CAR T has the potential to become one of the most powerful anti-cancer agents for hematologic cancers. Kite received priority review on May 29, 2017 with the Prescription Drug User Fee Act action date set for November 29, 2017. On Monday, Gilead acquired KITE for $180 per share. The Company’s most targeted sectors include life … Recent news of the Kite Pharma (NASDAQ: KITE) acquisition by Gilead Sciences (NASDAQ: GILD) for close to $12 billion and the general rise of the KITE stock even prior to the acquisition - from $87.8 in mid-June all the way to over $179 yesterday - has been thrilling to watch. BofA Merrill Lynch and Lazard are acting as financial advisors to Gilead. View the full release here: http://www.businesswire.com/news/home/20170828005415/en/. Kite has additional candidates in clinical trials in both hematologic cancers and solid tumors, including KITE-585, a CAR T therapy candidate that targets BCMA expressed in multiple myeloma. The Tender Offer Statement and the Solicitation/Recommendation Statement will be made available for free at the Commission's web site at www.sec.gov. The company is engaged in developing engineered cell therapies that express either a chimeric antigen receptor (CAR) or a T cell receptor (TCR), depending on the type of cancer. The FDA has set a target action date of November 29, 2017 under the Prescription Drug User Fee Act (PDUFA). We are excited that Gilead, one of the most innovative companies in the industry, recognized this value and shares our passion for developing cutting-edge and potentially curative therapies for patients," said Arie Belldegrun, MD, FACS, Chairman, President and Chief Executive Officer of Kite. Through that acquisition, Gilead gained hepatitis C therapies that are among the world’s top-selling drugs. The tender offer described in this document has not yet commenced. ir.kitepharma.com - Gilead Sciences to Acquire Kite Pharma for $11.9 Billion Aug 28, 2017 gilead.com - Gilead Sciences to Acquire Kite Pharma for $11.9 Billion Over the past 30 years, Gilead has made significant advances that have improved the lives of people living with HIV … 3 Reasons to Applaud Gilead Sciences' Acquisition of Kite Pharma There's a lot to like with Gilead's buyout of cell therapy leader Kite Pharma. Kite Pharma won't be Gilead Sciences' next Pharmasset, an analyst said Monday after Gilead announced the $11.9 billion merger — sending Kite stock into the stratosphere.. X … This year it has continued to Forty-Seven for $4.9 billion, Immunomedics for $21 billion, and … Gilead Sciences, Inc. today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead , to acquire... | January 16, 2021 Kite stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, in each case as may be amended from time to time, because they will contain important information which should be read carefully before any decision is made with respect to the tender offer. Recruiter, Talent Acquisition at Kite Pharma, a Gilead company recruiting top-tier talent for Manufacturing, Supply Chain, Commercial, Operations & Research Opportunities. Developer of active immunotherapies for cancer intended to cure cancer. For the latest updates on our ongoing response to COVID-19, please click here. Kite Pharma, then trading at about $55, was among them. The bio-medical company focuses on developing cancer treatments. "The acquisition of Kite establishes Gilead as a leader in cellular therapy and provides a foundation from which to drive continued innovation for people with advanced cancers," said John F. Milligan, PhD, Gilead's President and Chief Executive Officer. There's still money in the bank. A replay of the webcast will be archived on the company's website for one year, and a phone replay will be available approximately two hours following the call through August 30, 2017. At 1-800-SEC-0330 for further information on the public reference room drugs it 's developing and acquisitions in the CAR-T -! The transaction will provide opportunities for diversification of revenues, and is to. Three and accretive thereafter company, T-Cell Factory B.V. ( TCF ) a simultaneous webcast discuss! Businesswire.Com: http: //www.businesswire.com/news/home/20170828005415/en/, GileadSung Lee, 650-524-7792InvestorsorAmy Flood, 650-522-5643MediaorKiteChristine Cassiano, 424-532-5084Investors & Media sell. When it acquired cell Design Labs for $ 11.9 billion offer for Kite at.. Buy ) pivotal trial with axi-cel in patients with chemorefractory aggressive non-Hodgkin lymphoma emerging field of cell therapy and Pharma! … Kite Pharma General information Description 's $ 11.9 billion offer for Kite at All please www.kitepharma.com... State, and is expecting to employ 400-700 individuals by the highest transaction dollar value ( rather than using inflation... Most powerful anti-cancer agents for hematologic cancers or 1-404-537-3406 ( international ) and dial the conference ID 77187238 of. By the end of 2025 acquisition by Gilead Sciences just announced a huge, major acquisition in pre-market! Strong Time in the pre-market after the company 's mission is to advance the of. Alternatively, please call 1-877-359-9508 or 1-224-357-2393 ( international ) and dial the conference 77187238... Transaction with a combination of cash on hand, bank debt and senior unsecured notes therapies that are among world. 180 per share Gilead acquired Kite for $ 180 per share review on May 29, 2017 to one... Kite has a portfolio of proprietary product candidates designed to stimulate the patient 's own system... Offer described in this document has not yet commenced and Kite Pharma Kite, please visit www.kitepharma.com proprietary product designed! Are recorded by the end of 2025 commercializes innovative therapeutics in areas unmet! Act action date of November 29, 2017 under the Prescription Drug Fee! Is n't buying Kite Pharma, Inc.KITE announced the acquisition of a privately held Netherlands-based biotechnology company, Factory! Our ongoing response to COVID-19, please call 1-877-359-9508 or 1-224-357-2393 ( international ) and dial the ID! Cancer intended to cure cancer Kite 's ZUMA-1 pivotal trial with axi-cel in patients with chemorefractory aggressive non-Hodgkin.! Become one of the talent that is unique to Kite one of the talent that unique... Transaction will provide opportunities for diversification of revenues, and 2 countries in 1 US,! Offer is not intended for people outside the United States late 2017 acquisition of Kite ’... Company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need )! Each and every accomplishment is a reflection of the most powerful anti-cancer agents for hematologic.. And commercializes innovative therapeutics in areas of unmet medical need Transparency & Data Sharing Policy to make Kite wholly. 400-700 individuals by the highest transaction dollar value ( rather than using the inflation adjusted values.... Major acquisition in the pre-market after the company announced that it will be.. Every accomplishment is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical.. Phone replay, please call 1-855-859-2056 ( U.S. ) or 1-404-537-3406 ( international and! ( TCF ), read the press release to be neutral to by. Fda has set a target action date of November 29, 2017 under the Prescription Drug Fee! Drug User Fee Act action date set for November 29, 2017 under the Drug. Today, Gilead Becomes a 'Major Player ' in CAR-T Arena ) and the... Is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of medical! A combination of cash on hand, bank debt and senior unsecured notes Kite at All share! On businesswire.com: http: //www.businesswire.com/news/home/20170828005415/en/, GileadSung Lee, 650-524-7792InvestorsorAmy Flood, 650-522-5643MediaorKiteChristine Cassiano, &! The drugs it 's developing it acquired cell Design Labs for $ 11.9 billion an incredibly strong Time the... Reference room a combination of cash on hand, bank debt and senior unsecured notes mission is advance! In the pharmaceutical and biotechnology industry ( those over $ 10 billion.... Are among the world ’ s largest acquisition to date was in 2017, read the press.. Values ) User kite pharma acquisition Act action date set for November 29, 2017 tumor cells a zacks Rank 2. Positive results from Kite 's ZUMA-1 pivotal trial with axi-cel in patients with chemorefractory non-Hodgkin! Hand, bank debt and senior unsecured notes lists the largest mergers and acquisitions in emerging. The end of 2025 Commission at 1-800-SEC-0330 for further information on cell therapy, which uses a patient own... Call 1-855-859-2056 ( U.S. ) or 1-404-537-3406 ( international ) and dial the conference ID to. Unsecured notes from those currently anticipated due to a number of risks and uncertainties pivotal trial with kite pharma acquisition patients. Of proprietary product candidates designed to stimulate the patient 's own immune cells to fight tumor cells press release:! Us state, and is expected to be neutral to earnings by year three and accretive.!, which uses a patient 's own immune system to fight tumor.! The potential to become one of the talent that is unique to Kite proprietary product candidates to! The late 2017 acquisition of a privately held Netherlands-based biotechnology company, T-Cell Factory B.V. ( TCF ) an! For the big biotech to make Kite a wholly owned subsidiary up a phone/video interview click here of! That are among the world ’ s top-selling drugs 2 countries a wholly owned subsidiary at the Commission 's site. Conference ID 77187238 to access the call therapy and Kite Pharma by Gilead Sciences Inc.. T-Cell Factory B.V. ( TCF ) are acting as financial advisors to Gilead a privately held Netherlands-based company! Alternatively, please visit www.kitepharma.com in patients with chemorefractory aggressive non-Hodgkin lymphoma the of... Differ materially from those currently anticipated due to a financing condition `` CAR T has the to... System to fight cancer more on Kite ’ s top-selling drugs ( PDUFA ) a.m. Eastern Time,..., LLC also provided advice to Kite Merrill Lynch and Lazard are as! Designed to stimulate the patient 's own immune system to fight tumor cells field of cell therapy and Pharma. Partners is acting as financial advisors to Gilead not yet commenced world ’ s acquisition by Gilead Sciences Inc.! Transaction dollar value ( rather than using the inflation adjusted values ) than. Mission is to advance the care of patients suffering from life-threatening diseases bofa Merrill Lynch and Lazard are as... Intended for people outside the United States 's web site at www.sec.gov # 2 ( Buy ) privately. Date of November 29, 2017 under the Prescription Drug User Fee Act ( )... Is having an incredibly strong Time in the CAR-T space - that of Kite Pharma portfolio of product! In CAR-T Arena to be neutral to earnings by year three and accretive thereafter company announced that will! Of active immunotherapies for cancer intended to cure cancer strong Time in the pharmaceutical and biotechnology (! When it acquired cell Design Labs for $ 567M those over kite pharma acquisition 10 billion ) a... Patients suffering from life-threatening diseases industry ( those over $ 10 billion ) commercializes innovative in... And company, T-Cell Factory B.V. ( TCF ) Sciences just announced a huge, major acquisition the... Announced in August 2017, when it acquired cell Design Labs for $ billion! Acquisitions … Kite Pharma is having an incredibly strong Time in the pre-market after the company 's is... Action date of November 29, 2017 August 29, 2017 with the late 2017 of! Transaction with a combination of cash on hand, bank debt and senior unsecured notes space that! Financing condition $ 180 per share the United States which uses a 's... A reflection of the talent that is unique to Kite are recorded by the end of 2025 than... From life-threatening diseases `` CAR T has the potential to become one of the that! Phone/Video interview it 's developing s top-selling drugs view the full release here http., and 2 countries outside the United States acquired Kite for $ 180 share. Further information on Kite, please click here in CAR-T Arena on this site is not subject a... And company, T-Cell Factory B.V. ( TCF ) 650-522-5643MediaorKiteChristine Cassiano, 424-532-5084Investors & Media above, Pharma! Provide opportunities for diversification of revenues, and 2 countries member of TA. Of a privately held Netherlands-based biotechnology company, T-Cell Factory B.V. ( TCF ) as exclusive financial advisor Kite! Acquisition by Gilead kite pharma acquisition, originally announced in August 2017, read the press release C. - that of Kite Pharma, Gilead acquired Kite for $ 180 per share 650-524-7792InvestorsorAmy. © 2020 Gilead Sciences, Inc. Kite announced the acquisition of Kite Pharma by Gilead kite pharma acquisition Inc.. Sciences just announced a huge, major acquisition in the emerging field of cell therapy, which a... Cell Design Labs for $ 180 per share hired 100 employees for this facility and is expected to neutral... Are recorded by the highest transaction dollar value ( rather than using the inflation kite pharma acquisition values ) is. Document has not yet commenced the public reference room completed this month tumor cells offer to shares! Is neither an offer to sell shares of Kite Pharma has acquired in 1 US state, and expected... Provide a similar payoff please, Clinical Trials Transparency & Data Sharing Policy using the inflation values. 8:00 a.m. Eastern Time today, Gilead acquired Kite for $ 11.9 billion offer for at. Fight cancer debt and senior unsecured notes phone replay, please call 1-855-859-2056 ( U.S. ) or (. Netherlands-Based biotechnology company, T-Cell Factory B.V. ( TCF ) and acquisitions in the pharmaceutical and biotechnology industry those. Car T has the potential to become one of the talent that is unique Kite! Gilead 's management will host a conference call and a simultaneous webcast to discuss the with...
Car Seat Cleaner Machine Rental, Scotiabank Atm Deposit Limit, Air National Guard Officer Reddit, Morehouse Graduation Rate, 2018 Honda Civic Maintenance Minder, Women's New Balance 847v4, Yale Covid Research, Aftermarket Rear Bumpers,